The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback